CNBC
26 Nov 2025, 17:18 UTC · 42w ago
Verdict
Headline takes no side. We score NVO −0.60 across four claims — strongly bearish.
−0.60strongly bearish
More negative than 82% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
President Trump has implemented a 'Most Favored Nation' pricing policy to tie U.S. drug prices to lower international rates.
So whatLinking U.S. prices to lower global benchmarks threatens the primary high-margin revenue stream for global pharmaceutical companies.
More negative than 98% of claims this week
CMS announced negotiated prices for 15 blockbuster drugs for 2027, including a 71% discount for Novo Nordisk's Ozempic.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
Novo Nordisk and Eli Lilly reached deals to lower weight-loss drug prices for Medicare/Medicaid beneficiaries and consumers via TrumpRx.gov.
So whatLower prices per unit reduce margins, though this may be partially offset by higher volume growth from broader access.
More negative than 73% of claims this week
European pharmaceutical companies are increasing U.S. investments and pursuing NYSE listings to mitigate tariff risks and access capital.
More positive than 53% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
Facing a 71% discount on Ozempic, leadership changes due to US market failures, and mandatory price cuts on Wegovy.
More negative than 77% of ticker scores this week
Facing price discounts on Calquence and pressure to cut prices via deals with the Trump administration.
More negative than 77% of ticker scores this week
Facing significant price discounts (73-83%) on Trelegy and Breo and pressure to cut prices.
More negative than 74% of ticker scores this week
Agreed to slash prices for Zepbound for Medicare/Medicaid beneficiaries and direct consumers.
More negative than 74% of ticker scores this week
Announced deals with the Trump administration to cut drug prices.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
2d ago
−10.9%
Price agrees with the score
$41.94 vs $47.06 close before publication (Nov 25) · not market-adjusted
NVO chart →
